The California Supreme Court has ruled that attorneys who file class actions over employment and product liability matters should be allowed better access to the contact information of individuals who may help strengthen their cases.
Plaintiffs alleging that GlaxoSmithKline PLC knew about risks related to adolescents’ use of antidepressant Paxil, but failed to warn doctors and the public, were denied class certification Thursday.
The Ontario Superior Court of Justice has granted class action certification in a $100-million lawsuit that claims the acid reflux drug Prepulsid caused serious cardiac arrhythmias and several deaths.
Bayer Corp. has agreed to pay $8 million to 30 states to settle allegations that the drug company failed to adequately warn consumers about the safety risks associated with recalled cholesterol-lowering drug Baycol.
In a setback for General Motors Corp., a United States Court has dismissed a $900 million claim against insurance company Royal & Sun Alliance Insurance Group Plc brought by the troubled auto company for asbestos-related damages.
One of the three Kentucky lawyers accused of siphoning off money from a $200 million settlement involving Wyeth’s diet drug combination fen-phen has admitted that he and his colleagues destroyed crucial evidence in the case.
Nearly three years after criminal charges were settled in Pfizer Inc.’s illegal marketing of the epilepsy drug Neurontin, a federal judge is considering whether or not to grant class action status in nearly 200 consolidated civil lawsuits.
In another victory for Merck & Co., a woman who blamed her husband’s death on the painkiller Vioxx dropped her lawsuit against the pharmaceutical company on Monday, five weeks before it was scheduled to go to trial.
The third trial over Wyeth Pharmaceuticals’ controversial hormone replacement drug got underway Monday in Arkansas.
Shell Oil Co. on Monday appealed a federal court's decision to certify a class of property owners who sued the oil giant over a toxic chemical leak that allegedly contaminated Chicago-area wells.
Fresh off a $495 million product-liability settlement over Zyprexa, Eli Lilly & Co. is facing more scrutiny, with Illinois and Vermont requesting that the pharmaceutical giant hand over material detailing how it marketed the top-selling schizophrenia drug.
Jurors have failed to reach a unanimous decision in two product liability cases alleging that Merck & Co.’s controversial painkiller Vioxx induced heart attacks.
Consumers have brought a lawsuit against Hewlett-Packard, alleging that the company doesn’t tell its customers that its printer cartridges expire even if they still have ink.
The latest in a growing number of law suits against the makers of an anti-psychotic medication has labeled Astrazenenica contemptible for allegedly misleading the public about life-threatening side-effects of its popular drug.
As an increasing number of U.S. companies look toward the Indian market, a spate of U.S. law firms are shoring up their India-focused practices ahead of an expected wave of cross-border litigation and transactions.
Medical device maker Stryker Corp. faces a class action for selling a pain-relief device which allegedly caused permanent damage to injured patients.
Threatening to usher in a new wave of Vioxx lawsuits, a New Jersey appeals court has revived a proposed class action that seeks to force the pharmaceutical giant to cover medical-surveillance tests for individuals who took the controversial painkiller but have yet to suffer from any health problems.
In a blow to a group of Pennsylvania factory workers, a federal appeals court has granted Fenn Manufacturing Corp.’s motion for a new trial in a case involving a machine that allegedly causes permanent hand injuries.
The U.S. Food and Drug Administration revealed Thursday that it intends to ask Congress to authorize an $87.4 million increase to its prescription drug user fee program in order to upgrade its drug safety program and increase the development of new medications in the coming years.
Eli Lilly & Co. said Thursday that it will record charge of $495 million in the fourth quarter to settle product-liability claims related to the schizophrenia drug Zyprexa.